Grifols, S.A. (GRFS) Stock Competitors & Peer Comparison
See (GRFS) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GRFS | $7.53 | +2.66% | 6.2B | 10.49 | $0.70 | +2.40% |
| LLY | $1,148.99 | -0.01% | 1.1T | 40.64 | $28.15 | +0.57% |
| JNJ | $237.94 | +2.49% | 570.5B | 27.43 | $8.64 | +2.20% |
| ABBV | $225.67 | +1.16% | 398.3B | 109.96 | $2.05 | +3.00% |
| MRK | $120.43 | +0.76% | 295.4B | 33.69 | $3.55 | +2.79% |
| NVS | $153.30 | +4.70% | 284.5B | 21.36 | $6.98 | +3.20% |
| AZN | $180.46 | -0.60% | 284.5B | 27.63 | $6.64 | +1.79% |
| AMGN | $353.21 | +2.16% | 186B | 23.96 | $14.38 | +2.90% |
| GILD | $124.57 | -2.76% | 155.8B | 14.99 | $8.37 | +2.63% |
| PFE | $26.30 | +2.63% | 146.5B | 19.62 | $1.31 | +6.72% |
Stock Comparison
GRFS vs LLY Comparison June 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 6.2B. In comparison, LLY has a market cap of 1.1T. Regarding current trading prices, GRFS is priced at $7.53, while LLY trades at $1,148.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 10.49, whereas LLY's P/E ratio is 40.64. In terms of profitability, GRFS's ROE is +0.08%, compared to LLY's ROE of +1.01%. Regarding short-term risk, GRFS is less volatile compared to LLY. This indicates potentially lower risk in terms of short-term price fluctuations for GRFS.Check LLY's competition here
GRFS vs JNJ Comparison June 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 6.2B. In comparison, JNJ has a market cap of 570.5B. Regarding current trading prices, GRFS is priced at $7.53, while JNJ trades at $237.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 10.49, whereas JNJ's P/E ratio is 27.43. In terms of profitability, GRFS's ROE is +0.08%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, GRFS is less volatile compared to JNJ. This indicates potentially lower risk in terms of short-term price fluctuations for GRFS.Check JNJ's competition here
GRFS vs ABBV Comparison June 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 6.2B. In comparison, ABBV has a market cap of 398.3B. Regarding current trading prices, GRFS is priced at $7.53, while ABBV trades at $225.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 10.49, whereas ABBV's P/E ratio is 109.96. In terms of profitability, GRFS's ROE is +0.08%, compared to ABBV's ROE of +0.68%. Regarding short-term risk, GRFS is less volatile compared to ABBV. This indicates potentially lower risk in terms of short-term price fluctuations for GRFS.Check ABBV's competition here
GRFS vs MRK Comparison June 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 6.2B. In comparison, MRK has a market cap of 295.4B. Regarding current trading prices, GRFS is priced at $7.53, while MRK trades at $120.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 10.49, whereas MRK's P/E ratio is 33.69. In terms of profitability, GRFS's ROE is +0.08%, compared to MRK's ROE of +0.18%. Regarding short-term risk, GRFS is less volatile compared to MRK. This indicates potentially lower risk in terms of short-term price fluctuations for GRFS.Check MRK's competition here
GRFS vs NVS Comparison June 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 6.2B. In comparison, NVS has a market cap of 284.5B. Regarding current trading prices, GRFS is priced at $7.53, while NVS trades at $153.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 10.49, whereas NVS's P/E ratio is 21.36. In terms of profitability, GRFS's ROE is +0.08%, compared to NVS's ROE of +0.32%. Regarding short-term risk, GRFS is more volatile compared to NVS. This indicates potentially higher risk in terms of short-term price fluctuations for GRFS.Check NVS's competition here
GRFS vs AZN Comparison June 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 6.2B. In comparison, AZN has a market cap of 284.5B. Regarding current trading prices, GRFS is priced at $7.53, while AZN trades at $180.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 10.49, whereas AZN's P/E ratio is 27.63. In terms of profitability, GRFS's ROE is +0.08%, compared to AZN's ROE of +0.22%. Regarding short-term risk, GRFS is less volatile compared to AZN. This indicates potentially lower risk in terms of short-term price fluctuations for GRFS.Check AZN's competition here
GRFS vs AMGN Comparison June 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 6.2B. In comparison, AMGN has a market cap of 186B. Regarding current trading prices, GRFS is priced at $7.53, while AMGN trades at $353.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 10.49, whereas AMGN's P/E ratio is 23.96. In terms of profitability, GRFS's ROE is +0.08%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, GRFS is less volatile compared to AMGN. This indicates potentially lower risk in terms of short-term price fluctuations for GRFS.Check AMGN's competition here
GRFS vs GILD Comparison June 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 6.2B. In comparison, GILD has a market cap of 155.8B. Regarding current trading prices, GRFS is priced at $7.53, while GILD trades at $124.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 10.49, whereas GILD's P/E ratio is 14.99. In terms of profitability, GRFS's ROE is +0.08%, compared to GILD's ROE of +0.42%. Regarding short-term risk, GRFS is less volatile compared to GILD. This indicates potentially lower risk in terms of short-term price fluctuations for GRFS.Check GILD's competition here
GRFS vs PFE Comparison June 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 6.2B. In comparison, PFE has a market cap of 146.5B. Regarding current trading prices, GRFS is priced at $7.53, while PFE trades at $26.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 10.49, whereas PFE's P/E ratio is 19.62. In terms of profitability, GRFS's ROE is +0.08%, compared to PFE's ROE of +0.08%. Regarding short-term risk, GRFS is less volatile compared to PFE. This indicates potentially lower risk in terms of short-term price fluctuations for GRFS.Check PFE's competition here
GRFS vs BMY Comparison June 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 6.2B. In comparison, BMY has a market cap of 115.3B. Regarding current trading prices, GRFS is priced at $7.53, while BMY trades at $57.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 10.49, whereas BMY's P/E ratio is 15.82. In terms of profitability, GRFS's ROE is +0.08%, compared to BMY's ROE of +0.39%. Regarding short-term risk, GRFS is less volatile compared to BMY. This indicates potentially lower risk in terms of short-term price fluctuations for GRFS.Check BMY's competition here
GRFS vs SNY Comparison June 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 6.2B. In comparison, SNY has a market cap of 107.5B. Regarding current trading prices, GRFS is priced at $7.53, while SNY trades at $44.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 10.49, whereas SNY's P/E ratio is 19.62. In terms of profitability, GRFS's ROE is +0.08%, compared to SNY's ROE of +0.11%. Regarding short-term risk, GRFS is more volatile compared to SNY. This indicates potentially higher risk in terms of short-term price fluctuations for GRFS.Check SNY's competition here
GRFS vs GSK Comparison June 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 6.2B. In comparison, GSK has a market cap of 103.1B. Regarding current trading prices, GRFS is priced at $7.53, while GSK trades at $52.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 10.49, whereas GSK's P/E ratio is 13.52. In terms of profitability, GRFS's ROE is +0.08%, compared to GSK's ROE of +0.28%. Regarding short-term risk, GRFS is less volatile compared to GSK. This indicates potentially lower risk in terms of short-term price fluctuations for GRFS.Check GSK's competition here
GRFS vs ZTS Comparison June 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 6.2B. In comparison, ZTS has a market cap of 34.5B. Regarding current trading prices, GRFS is priced at $7.53, while ZTS trades at $79.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 10.49, whereas ZTS's P/E ratio is 13.48. In terms of profitability, GRFS's ROE is +0.08%, compared to ZTS's ROE of +0.62%. Regarding short-term risk, GRFS is less volatile compared to ZTS. This indicates potentially lower risk in terms of short-term price fluctuations for GRFS.Check ZTS's competition here
GRFS vs BIIB Comparison June 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 6.2B. In comparison, BIIB has a market cap of 29.4B. Regarding current trading prices, GRFS is priced at $7.53, while BIIB trades at $201.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 10.49, whereas BIIB's P/E ratio is 21.41. In terms of profitability, GRFS's ROE is +0.08%, compared to BIIB's ROE of +0.08%. Regarding short-term risk, GRFS is less volatile compared to BIIB. This indicates potentially lower risk in terms of short-term price fluctuations for GRFS.Check BIIB's competition here
GRFS vs HZNP Comparison June 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 6.2B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, GRFS is priced at $7.53, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 10.49, whereas HZNP's P/E ratio is 61.86. In terms of profitability, GRFS's ROE is +0.08%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, GRFS is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for GRFS.Check HZNP's competition here
GRFS vs OGN Comparison June 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 6.2B. In comparison, OGN has a market cap of 3.5B. Regarding current trading prices, GRFS is priced at $7.53, while OGN trades at $13.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 10.49, whereas OGN's P/E ratio is 14.41. In terms of profitability, GRFS's ROE is +0.08%, compared to OGN's ROE of +0.30%. Regarding short-term risk, GRFS is more volatile compared to OGN. This indicates potentially higher risk in terms of short-term price fluctuations for GRFS.Check OGN's competition here
GRFS vs CELG-RI Comparison June 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 6.2B. In comparison, CELG-RI has a market cap of 219.5M. Regarding current trading prices, GRFS is priced at $7.53, while CELG-RI trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 10.49, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, GRFS's ROE is +0.08%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, GRFS is more volatile compared to CELG-RI. This indicates potentially higher risk in terms of short-term price fluctuations for GRFS.Check CELG-RI's competition here
GRFS vs CTOR Comparison June 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 6.2B. In comparison, CTOR has a market cap of 66.9M. Regarding current trading prices, GRFS is priced at $7.53, while CTOR trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 10.49, whereas CTOR's P/E ratio is -1.50. In terms of profitability, GRFS's ROE is +0.08%, compared to CTOR's ROE of -0.99%. Regarding short-term risk, GRFS is less volatile compared to CTOR. This indicates potentially lower risk in terms of short-term price fluctuations for GRFS.Check CTOR's competition here
GRFS vs SCLX Comparison June 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 6.2B. In comparison, SCLX has a market cap of 59.8M. Regarding current trading prices, GRFS is priced at $7.53, while SCLX trades at $8.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 10.49, whereas SCLX's P/E ratio is -0.17. In terms of profitability, GRFS's ROE is +0.08%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, GRFS is less volatile compared to SCLX. This indicates potentially lower risk in terms of short-term price fluctuations for GRFS.Check SCLX's competition here
GRFS vs MIRA Comparison June 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 6.2B. In comparison, MIRA has a market cap of 41M. Regarding current trading prices, GRFS is priced at $7.53, while MIRA trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 10.49, whereas MIRA's P/E ratio is -0.77. In terms of profitability, GRFS's ROE is +0.08%, compared to MIRA's ROE of -1.41%. Regarding short-term risk, GRFS is more volatile compared to MIRA. This indicates potentially higher risk in terms of short-term price fluctuations for GRFS.Check MIRA's competition here
GRFS vs SRXH Comparison June 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 6.2B. In comparison, SRXH has a market cap of 4.1M. Regarding current trading prices, GRFS is priced at $7.53, while SRXH trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 10.49, whereas SRXH's P/E ratio is -0.71. In terms of profitability, GRFS's ROE is +0.08%, compared to SRXH's ROE of +8.75%. Regarding short-term risk, GRFS is less volatile compared to SRXH. This indicates potentially lower risk in terms of short-term price fluctuations for GRFS.Check SRXH's competition here
GRFS vs SCLXW Comparison June 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 6.2B. In comparison, SCLXW has a market cap of 1.4M. Regarding current trading prices, GRFS is priced at $7.53, while SCLXW trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 10.49, whereas SCLXW's P/E ratio is N/A. In terms of profitability, GRFS's ROE is +0.08%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, GRFS is more volatile compared to SCLXW. This indicates potentially higher risk in terms of short-term price fluctuations for GRFS.Check SCLXW's competition here
GRFS vs CRXT Comparison June 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 6.2B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, GRFS is priced at $7.53, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 10.49, whereas CRXT's P/E ratio is -0.02. In terms of profitability, GRFS's ROE is +0.08%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, GRFS is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for GRFS.Check CRXT's competition here
GRFS vs BDSIW Comparison June 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 6.2B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, GRFS is priced at $7.53, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 10.49, whereas BDSIW's P/E ratio is N/A. In terms of profitability, GRFS's ROE is +0.08%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, GRFS is less volatile compared to BDSIW. This indicates potentially lower risk in terms of short-term price fluctuations for GRFS.Check BDSIW's competition here